Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curatis Holding AGXSWX:CURN 30 Cash-to-Debt is No Debt (1) as of Dec. 2025, which is 100% below its 10-year median of 0.45. GuruFocus rates XSWX:CURN with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 982 Drug Manufacturers companies, Curatis Holding AG ranks better than 99.69% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Curatis Holding AG's cash to debt ratio for the quarter that ended in Dec. 2025 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Curatis Holding AGcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Curatis Holding AG's Cash-to-Debt or its related term are showing as below:
XSWX:CURN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07 Med: 0.45 Max: No Debt
Current: No Debt
During the past 5 years, Curatis Holding AG's highest Cash to Debt Ratio was No Debt. The lowest was 0.07. And the median was 0.45.
XSWX:CURN's Cash-to-Debt is ranked better than 99.69% of 982
companies
in the Drug Manufacturers industry
Industry Median: 0.97
vs XSWX:CURN: No Debt
Curatis Holding AG (XSWX:CURN) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Curatis Holding AG Cash-to-Debt Related Terms
Curatis Holding AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:CURN vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's Cash-to-Debt falls into.
Curatis Holding AG's Cash to Debt Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
Curatis Holding AG had no debt (1).
Curatis Holding AG's Cash to Debt Ratio for the quarter that ended in Dec. 2025 is calculated as:
Curatis Holding AG had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Curatis Holding AG (XSWX:CURN) has a Cash-to-Debt of No Debt (1) as of Dec. 2025. This is 122% above median its historical median of 0.45. Over the past decade, Curatis Holding AG's Cash-to-Debt has ranged from 0.07 to 10,000.00. According to the industry distribution chart, Curatis Holding AG ranks #3 out of 982 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Curatis Holding AG's Cash-to-Debt too high?
Curatis Holding AG's current Cash-to-Debt of No Debt (1) is 122% above median its 10-year median of 0.45. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 10,000.00. Based on the distribution chart, Curatis Holding AG ranks #3 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curatis Holding AG has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #3 out of 982 companies for Cash-to-Debt. This places Curatis Holding AG in the top 0% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.97. Historically, Curatis Holding AG's own Cash-to-Debt has ranged from 0.07 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current Cash-to-Debt is No Debt (1), which is 122% above median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 122% above median its 10-year median of 0.45. Curatis Holding AG's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current Cash-to-Debt is No Debt (1) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
30GF Score
Get the complete analysis for XSWX:CURN
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
